MIRA's KETAMIR-2 Demonstrates Enhanced Efficacy and Safety
KETAMIR-2 surpasses current pain and inflammation treatments in preclinical studies.
MIRA Pharmaceuticals announced that its investigational drug KETAMIR-2 has shown superior performance in preclinical studies compared to existing treatments for pain management and inflammation. KETAMIR-2, which is part of MIRA's novel class of synthetic cannabinoid compounds, outperformed current market therapies in terms of efficacy and safety.
The compound demonstrated significant improvements in reducing pain and inflammation while minimizing side effects commonly associated with similar drugs. MIRA aims to continue advancing KETAMIR-2 through further clinical development.
This breakthrough aligns with MIRA’s mission to provide innovative therapies for unmet medical needs in pain management.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
Pharming Group Gains FDA Approval for Leniolisib in Children Aged 4–11 with APDS
Lonza Builds Oregon Spray-Drying Facility To Expand SDD Capacity
Discussion